In the stage IV setting, ICIs have not achieved the desired effect in the treatment of oncogene-driven NSCLC, such as EGFR exon 19 and 21 mutations and ALK and ROS-1 rearrangements, either first- or second-setting [145, 146]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.